Which has preferable earnings and valuation, ALNT or CTKB?

Allient has higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allient $554.48M 2.63 $22.03M $1.43 59.97 Cytek Biosciences $201.49M 2.60 -$66.54M -$0.57 N/A

Does the media refer more to ALNT or CTKB?

In the previous week, Allient had 2 more articles in the media than Cytek Biosciences. MarketBeat recorded 4 mentions for Allient and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.62 beat Allient's score of 0.47 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allient 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytek Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, CTKB or ALMR?

Alamar Biosciences has lower revenue, but higher earnings than Cytek Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytek Biosciences $201.49M 2.60 -$66.54M -$0.57 N/A Alamar Biosciences $87.16M 17.11 N/A N/A N/A

Does the media prefer CTKB or ALMR?

In the previous week, Cytek Biosciences and Cytek Biosciences both had 2 articles in the media. Alamar Biosciences' average media sentiment score of 0.93 beat Cytek Biosciences' score of 0.62 indicating that Alamar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alamar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EYPT or CTKB?

In the previous week, Eyepoint Pharmaceuticals and Eyepoint Pharmaceuticals both had 2 articles in the media. Eyepoint Pharmaceuticals' average media sentiment score of 0.93 beat Cytek Biosciences' score of 0.62 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytek Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TRNS or CTKB?

In the previous week, Transcat and Transcat both had 2 articles in the media. Transcat's average media sentiment score of 1.08 beat Cytek Biosciences' score of 0.62 indicating that Transcat is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Transcat 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytek Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cytek Biosciences (CTKB) Competitors

$4.05 -0.08 (-1.94%)

Closing price 04:00 PM Eastern

Extended Trading

$4.03 -0.02 (-0.49%)

As of 06:42 PM Eastern

Compare

CTKB vs. ALNT, ALMR, EYPT, TRNS, and FEIM

Should you buy Cytek Biosciences stock or one of its competitors? MarketBeat compares Cytek Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cytek Biosciences include Allient (ALNT), Alamar Biosciences (ALMR), Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), and Frequency Electronics (FEIM). These companies are all part of the "measuring and control equipment" industry.

How does Cytek Biosciences compare to Allient?

Allient (NASDAQ:ALNT) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap measuring and control equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Allient has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

61.6% of Allient shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 15.0% of Allient shares are held by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Allient had 2 more articles in the media than Cytek Biosciences. MarketBeat recorded 4 mentions for Allient and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.62 beat Allient's score of 0.47 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allient	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allient has a net margin of 4.25% compared to Cytek Biosciences' net margin of -36.25%. Allient's return on equity of 12.47% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allient	4.25%	12.47%	6.37%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

Allient has higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allient	$554.48M	2.63	$22.03M	$1.43	59.97
Cytek Biosciences	$201.49M	2.60	-$66.54M	-$0.57	N/A

Allient presently has a consensus price target of $77.33, suggesting a potential downside of 9.83%. Cytek Biosciences has a consensus price target of $5.69, suggesting a potential upside of 40.43%. Given Cytek Biosciences' higher probable upside, analysts clearly believe Cytek Biosciences is more favorable than Allient.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allient	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Allient beats Cytek Biosciences on 13 of the 16 factors compared between the two stocks.

How does Cytek Biosciences compare to Alamar Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Alamar Biosciences (NASDAQ:ALMR) are both small-cap measuring and control equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

In the previous week, Cytek Biosciences and Cytek Biosciences both had 2 articles in the media. Alamar Biosciences' average media sentiment score of 0.93 beat Cytek Biosciences' score of 0.62 indicating that Alamar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alamar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.5% of Cytek Biosciences shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cytek Biosciences presently has a consensus target price of $5.69, suggesting a potential upside of 40.43%. Alamar Biosciences has a consensus target price of $30.00, suggesting a potential upside of 39.47%. Given Cytek Biosciences' higher possible upside, analysts clearly believe Cytek Biosciences is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alamar Biosciences	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Alamar Biosciences has lower revenue, but higher earnings than Cytek Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	2.60	-$66.54M	-$0.57	N/A
Alamar Biosciences	$87.16M	17.11	N/A	N/A	N/A

Alamar Biosciences has a net margin of 0.00% compared to Cytek Biosciences' net margin of -36.25%. Alamar Biosciences' return on equity of 0.00% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-36.25%	-10.07%	-7.56%
Alamar Biosciences	N/A	N/A	N/A

Summary

Alamar Biosciences beats Cytek Biosciences on 7 of the 11 factors compared between the two stocks.

How does Cytek Biosciences compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

In the previous week, Eyepoint Pharmaceuticals and Eyepoint Pharmaceuticals both had 2 articles in the media. Eyepoint Pharmaceuticals' average media sentiment score of 0.93 beat Cytek Biosciences' score of 0.62 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytek Biosciences has a net margin of -36.25% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Cytek Biosciences' return on equity of -10.07% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

Cytek Biosciences has higher revenue and earnings than Eyepoint Pharmaceuticals. Cytek Biosciences is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	32.95	-$231.96M	-$3.50	N/A
Cytek Biosciences	$201.49M	2.60	-$66.54M	-$0.57	N/A

Eyepoint Pharmaceuticals currently has a consensus price target of $31.80, suggesting a potential upside of 157.91%. Cytek Biosciences has a consensus price target of $5.69, suggesting a potential upside of 40.43%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Eyepoint Pharmaceuticals has a beta of 1.72, meaning that its stock price is 72% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

Summary

Eyepoint Pharmaceuticals beats Cytek Biosciences on 9 of the 16 factors compared between the two stocks.

How does Cytek Biosciences compare to Transcat?

Transcat (NASDAQ:TRNS) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap measuring and control equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Transcat has higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$331.88M	2.48	$5.38M	$0.58	151.79
Cytek Biosciences	$201.49M	2.60	-$66.54M	-$0.57	N/A

In the previous week, Transcat and Transcat both had 2 articles in the media. Transcat's average media sentiment score of 1.08 beat Cytek Biosciences' score of 0.62 indicating that Transcat is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Transcat	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.3% of Transcat shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 2.8% of Transcat shares are held by insiders. Comparatively, 10.4% of Cytek Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Transcat has a net margin of 1.62% compared to Cytek Biosciences' net margin of -36.25%. Transcat's return on equity of 5.84% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	1.62%	5.84%	3.78%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

Transcat presently has a consensus target price of $105.33, suggesting a potential upside of 19.64%. Cytek Biosciences has a consensus target price of $5.69, suggesting a potential upside of 40.43%. Given Cytek Biosciences' higher probable upside, analysts clearly believe Cytek Biosciences is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Transcat has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

Summary

Transcat beats Cytek Biosciences on 11 of the 16 factors compared between the two stocks.

How does Cytek Biosciences compare to Frequency Electronics?

Cytek Biosciences (NASDAQ:CTKB) and Frequency Electronics (NASDAQ:FEIM) are both small-cap measuring and control equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

In the previous week, Cytek Biosciences had 1 more articles in the media than Frequency Electronics. MarketBeat recorded 2 mentions for Cytek Biosciences and 1 mentions for Frequency Electronics. Frequency Electronics' average media sentiment score of 0.93 beat Cytek Biosciences' score of 0.62 indicating that Frequency Electronics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cytek Biosciences	Positive
Frequency Electronics	Positive

Cytek Biosciences presently has a consensus price target of $5.69, suggesting a potential upside of 40.43%. Frequency Electronics has a consensus price target of $43.67, suggesting a potential downside of 34.46%. Given Cytek Biosciences' higher possible upside, research analysts plainly believe Cytek Biosciences is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

Frequency Electronics has a net margin of 10.78% compared to Cytek Biosciences' net margin of -36.25%. Frequency Electronics' return on equity of 12.69% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-36.25%	-10.07%	-7.56%
Frequency Electronics	10.78%	12.69%	7.84%

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 58.6% of Frequency Electronics shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by insiders. Comparatively, 28.0% of Frequency Electronics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Frequency Electronics has lower revenue, but higher earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Frequency Electronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	2.60	-$66.54M	-$0.57	N/A
Frequency Electronics	$69.81M	9.39	$23.69M	$0.75	88.84

Cytek Biosciences has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Frequency Electronics has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Summary

Frequency Electronics beats Cytek Biosciences on 11 of the 17 factors compared between the two stocks.

Get Cytek Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTKB vs. The Competition

Export

Metric	Cytek Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$533.36M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	-7.11	10.45	20.85	21.87
Price / Sales	2.60	290.84	500.87	105.21
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	1.52	8.00	10.43	6.70
Net Income	-$66.54M	$23.89M	$3.56B	$337.26M
7 Day Performance	N/A	-3.49%	-1.39%	-1.41%
1 Month Performance	-12.15%	1.03%	0.86%	1.15%
1 Year Performance	16.71%	34.39%	19.42%	22.61%

Cytek Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTKB Cytek Biosciences	2.0666 of 5 stars	$4.05 -1.9%	$5.69 +40.4%	+16.0%	$533.36M	$201.49M	N/A	500	News Coverage
ALNT Allient	2.7662 of 5 stars	$86.92 -0.3%	$77.33 -11.0%	+160.6%	$1.48B	$554.48M	39.45	2,478
ALMR Alamar Biosciences	4.5167 of 5 stars	$20.13 +4.8%	$30.00 +49.0%	N/A	$1.40B	$87.16M	N/A	222
EYPT Eyepoint Pharmaceuticals	2.9241 of 5 stars	$11.77 +2.8%	$31.80 +170.2%	+31.8%	$959.98M	$31.37M	N/A	120	High Trading Volume
TRNS Transcat	3.4882 of 5 stars	$90.00 +0.3%	$105.33 +17.0%	+17.4%	$838.51M	$331.88M	48.52	1,413	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTKB) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytek Biosciences (CTKB) Competitors

CTKB vs. ALNT, ALMR, EYPT, TRNS, and FEIM

How does Cytek Biosciences compare to Allient?

Summary

How does Cytek Biosciences compare to Alamar Biosciences?

Summary

How does Cytek Biosciences compare to Eyepoint Pharmaceuticals?

Summary

How does Cytek Biosciences compare to Transcat?

Summary

How does Cytek Biosciences compare to Frequency Electronics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB vs. The Competition

Cytek Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytek Biosciences (CTKB) Competitors

CTKB vs. ALNT, ALMR, EYPT, TRNS, and FEIM

How does Cytek Biosciences compare to Allient?

Which has more risk & volatility, ALNT or CTKB?

Do insiders & institutionals hold more shares of ALNT or CTKB?

Does the media refer more to ALNT or CTKB?

Is ALNT or CTKB more profitable?

Which has preferable earnings and valuation, ALNT or CTKB?

Do analysts rate ALNT or CTKB?

Summary

How does Cytek Biosciences compare to Alamar Biosciences?

Does the media prefer CTKB or ALMR?

Do insiders and institutionals have more ownership in CTKB or ALMR?

Do analysts rate CTKB or ALMR?

Which has higher valuation and earnings, CTKB or ALMR?

Is CTKB or ALMR more profitable?

Summary

How does Cytek Biosciences compare to Eyepoint Pharmaceuticals?

Does the media favor EYPT or CTKB?

Is EYPT or CTKB more profitable?

Which has preferable earnings & valuation, EYPT or CTKB?

Do analysts rate EYPT or CTKB?

Do institutionals & insiders hold more shares of EYPT or CTKB?

Which has more volatility and risk, EYPT or CTKB?

Summary

How does Cytek Biosciences compare to Transcat?

Which has stronger valuation & earnings, TRNS or CTKB?

Does the media refer more to TRNS or CTKB?

Do institutionals and insiders hold more shares of TRNS or CTKB?

Is TRNS or CTKB more profitable?

Do analysts rate TRNS or CTKB?

Which has more risk & volatility, TRNS or CTKB?

Summary

How does Cytek Biosciences compare to Frequency Electronics?

Does the media refer more to CTKB or FEIM?

Do analysts prefer CTKB or FEIM?

Is CTKB or FEIM more profitable?

Do insiders and institutionals hold more shares of CTKB or FEIM?

Which has higher earnings & valuation, CTKB or FEIM?

Which has more risk & volatility, CTKB or FEIM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB vs. The Competition

Cytek Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools